Pfizer Inc
NYSE: PFE
$28.45
-$0.19 (-0.7%)
Closing Price on October 25, 2024
PFE Articles
Pfizer looks like it is out of the bid now for AstraZeneca. What looks increasingly obvious for a lackluster performance is that Pfizer may now simply be having an identity crisis.
Published:
ThinkstockEvery time the economy gets good again, and every time the stock market gets high again, waves of mergers and acquisitions begin taking place. The stock market’s bull run is now more than...
Published:
A new report from the global equity strategy team at Credit Suisse maintains that the best defensive sector now is large cap pharmaceuticals. Here are their top large cap pharmaceuticals to buy now.
Published:
Several things are taking place ahead of the end of May, and the number of pundits getting more worried about the markets seems to be on the rise. The problem is that there are just as many bullish...
Published:
Last Updated:
thinkstockMay 19, 2014: Markets opened lower on Monday but look to close the day on the upside, even if just barely. There was no economic news of note today, no major earnings results, and very...
Published:
Last Updated:
ThinkstockBig news from two of the market’s biggest names is making waves across Wall Street today as stocks advance through a quiet start to the week. The Dow Jones Industrial...
Published:
ThinkstockCreating the most popular product of the year will make consumers and investors happy. But making an all-time bestseller can transform an industry and define a business for decades. Many of...
Published:
thinkstockMay 6, 2014: Markets opened lower on Monday and sank slowly and surely for the rest of the day. The dollar weakened against the yen overnight removing some enthusiasm for risk in today’s...
Published:
Last Updated:
Merck has had its consumer products business on the market since the beginning of this year, and Tuesday it announced that it had sold the business to Germany-based Bayer for $14.2 billion.
Published:
Last Updated:
thinkstockMay 5, 2014: Markets opened lower on Monday but gamely pushed to the upside in midafternoon. General concern over the situation in Ukraine and a weaker outlook on global growth prospects...
Published:
Last Updated:
Drug giant Pfizer reported better-than-expected first-quarter 2014 earnings before markets opened Monday morning, but revenues fell short. Shares traded lower in the premarket.
Published:
Last Updated:
Jon OggEarnings season is far from over, but roughly three quarters of the stocks in the Standard & Poor’s 500 Index stocks have now reported their earnings for the first calendar quarter of...
Published:
British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion (about £50 a share) in cash and stock.
Published:
Last Updated:
thinkstockApril 28, 2014: Markets opened higher on Monday with little economic data to drive the market either up or down. Consequently shares fell then rose and look to be headed for small positive...
Published:
Last Updated:
The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it all back and then some through April 15.
Published: